EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PNA6, a Lactosyl Analogue of Angiotensin-(1-7), Reverses Pain Induced in Murine Models of Inflammation, Chemotherapy-Induced Peripheral Neuropathy, and Metastatic Bone Disease

Maha I Sulaiman, Wafaa Alabsi, Lajos Szabo, Meredith Hay, Robin Polt iD, Tally M Largent-Milnes iD, Todd W Vanderah

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241915007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Maha I Sulaiman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ 85721, USA. Hauptthemen laut MEDLINE: Neuralgia, Bone Neoplasms, Cancer Pain, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, NIDA NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pain is the most significant impairment and debilitating challenge for patients with bone metastasis. Therefore, the primary objective of current therapy is to mitigate and prevent the persistence of pain. Thus, cancer-induced bone pain is described as a multifaceted form of discomfort encompassing both inflammatory and neuropathic elements. We have developed a novel non-addictive pain therapeutic, PNA6, that is a derivative of the peptide Angiotensin-(1-7) and binds the Mas receptor to decrease inflammation-related cancer pain. In the present study, we provide evidence that PNA6 attenuates inflammatory, chemotherapy-induced peripheral neuropathy (CIPN) and cancer pain confined to the long bones, exhibiting longer-lasting efficacious therapeutic effects. PNA6, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-Lact)-amide, was successfully synthesized using solid phase peptide synthesis (SPPS). PNA6 significantly reversed inflammatory pain induced by 2% carrageenan in mice. A second murine model of platinum drug-induced painful peripheral neuropathy was established using oxaliplatin. Mice in the oxaliplatin-vehicle treatment groups demonstrated significant mechanical allodynia compared to the oxaliplatin-PNA6 treatment group mice. In a third study modeling a complex pain state, E0771 breast adenocarcinoma cells were implanted into the femur of female C57BL/6J wild-type mice to induce cancer-induced bone pain (CIBP). Both acute and chronic dosing of PNA6 significantly reduced the spontaneous pain behaviors associated with CIBP. These data suggest that PNA6 is a viable lead candidate for treating chronic inflammatory and complex neuropathic pain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuralgiaBone NeoplasmsCancer PainBreast NeoplasmsAntineoplastic AgentsMice, Inbred C57BLHyperalgesiaHumansAnimalsOxaliplatinDisease Models, AnimalFemaleMiceAngiotensin IPeptide FragmentsPainPeripheral Nervous System Diseases

Stichwörter der Autor:innen

Angiotensin-(1-7)PNA6breastcancermas receptorpain

Substanzen

OxaliplatinAntineoplastic Agentsangiotensin I (1-7)Angiotensin IPeptide Fragments

Autor:innen und Institutionen

  • Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ 85721, USA.
  • Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.
  • Skaggs Pharmaceutical Sciences Center, College of Pharmacy, The University of Arizona, 1703 E. Mabel St, Tucson, AZ 85721, USA.
  • The BIO5 Institute, The University of Arizona, Tucson, AZ 85721, USA.
  • Department of Physiology, The University of Arizona, Tucson, AZ 85721, USA.
  • Evelyn F. McKnight Brain Institute, The University of Arizona, Tucson, AZ 85721, USA.

ORCID-Profile: Robin Polt, Tally M Largent-Milnes

Förderung

  • NIDCR NIH HHS
  • NIDA NIH HHS
  • NCI NIH HHS
  • Comprehensive Pain and Addiction Center, University of Arizona Health Sciences

Zitieren

APA

Sulaiman, M. I., Alabsi, W., Szabo, L., Hay, M., Polt, R., Largent-Milnes, T. M., & Vanderah, T. W. (2023). PNA6, a Lactosyl Analogue of Angiotensin-(1-7), Reverses Pain Induced in Murine Models of Inflammation, Chemotherapy-Induced Peripheral Neuropathy, and Metastatic Bone Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241915007

Vancouver

Sulaiman MI, Alabsi W, Szabo L, Hay M, Polt R, Largent-Milnes TM, et al. PNA6, a Lactosyl Analogue of Angiotensin-(1-7), Reverses Pain Induced in Murine Models of Inflammation, Chemotherapy-Induced Peripheral Neuropathy, and Metastatic Bone Disease. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241915007

BibTeX
@article{Sulaiman2023,
  author = {Sulaiman, Maha I and Alabsi, Wafaa and Szabo, Lajos and Hay, Meredith and Polt, Robin and Largent-Milnes, Tally M and Vanderah, Todd W},
  title = {PNA6, a Lactosyl Analogue of Angiotensin-(1-7), Reverses Pain Induced in Murine Models of Inflammation, Chemotherapy-Induced Peripheral Neuropathy, and Metastatic Bone Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241915007}
}
Kostenlos starten →